Why the study?
Does low-dose colchicine reduce MACE in patients with coronary disease?
Does low-dose colchicine reduce MACE in patients with coronary disease?
Low-dose colchicine reduces ischemic events in coronary disease but does not improve overall survival due to an offsetting increase in non-cardiovascular deaths.
Supports low-dose colchicine to reduce ischemic events in coronary disease; confirms MACE benefit while highlighting no net survival gain from offsetting non-cardiovascular deaths.
Our meta-analysis indicates that low-dose colchicine reduced the risk of MACE as well as that of myocardial infarction, stroke, and the need for coronary revascularization in a broad spectrum of patients with coronary disease. There was no difference in all-cause mortality and fewer cardiovascular deaths were counterbalanced by more non-cardiovascular deaths.
No takes yet. Share an insight, caveat, or question.
Fiolet et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: